Sequent Scientific Ltd (VIYASH) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Sequent Scientific Ltd reported its highest quarterly sales in the last three years, reaching INR 3,908 million, an 18.7% increase year-over-year. This strong performance is attributed to margin improvement efforts, including pricing adjustments, product mix optimization, and cost management.
- Year-to-date revenue growth reached 14% compared to the same period last year.
- EBITDA pre-ESOP for the quarter saw a significant increase of 64% year-over-year, reaching INR 494 million. Year-to-date EBITDA pre-ESOP grew by 116%, reaching INR 1,424 million.
- Cumulative PBT for the first nine months grew by nearly 150% year-over-year, reaching INR 280 million.
- The company expressed confidence in continued improvement across all financial parameters.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.